Nicotine pouches are continuing to move further into the mainstream U.S. nicotine market, and recent federal decisions are giving consumers even more authorized products to choose from.
The Food and Drug Administration has authorized 11 new ZYN ULTRA nicotine pouch products from Swedish Match USA, adding several 9 mg options and an 11 mg version of Smooth. The decision came shortly after the agency authorized four additional on! products from Helix Innovations.
The latest actions highlight how quickly the nicotine pouch category is developing while also showing the level of regulatory review manufacturers must navigate before products can legally be marketed in the United States.
A Bigger ZYN ULTRA Selection
The newest ZYN ULTRA authorization covers a broad collection of flavors. The products include Chill, Citrus, Cool Mint, Deep Freeze, Menthol, Peppermint, Smooth, Spearmint, Wintergreen Chill, and Wintergreen.
Most of the newly authorized products contain 9 mg of nicotine, while Smooth is also available in an 11 mg version.
The expansion gives the ZYN ULTRA line more room to compete across different flavor preferences and nicotine levels. Mint and menthol remain heavily represented, but citrus and other flavor variations provide additional choices.
The higher-strength options are also notable as nicotine pouch manufacturers continue developing products designed around different levels of nicotine delivery.
Still, the FDA's decision represents authorization to market the products, not an endorsement that they are harmless.
The agency specifically explains that tobacco products receiving marketing authorization should not be described as “FDA approved.” Nicotine can cause dependence, and authorized products still carry risks.
on! Takes a Different Approach
Helix Innovations received authorization for four additional on! products earlier in August.
The new products include Rich Berry at 2 mg, Cappuccino at 2 mg, Cappuccino at 4 mg, and Autumn Spice at 2 mg.
The lineup creates a noticeable contrast with the newly authorized ZYN ULTRA products. While ZYN ULTRA includes several 9 mg products, the new on! offerings are concentrated at lower nicotine strengths.
The flavor selection is also broader than the traditional mint-focused image associated with nicotine pouches. Berry, coffee, and seasonal flavor concepts give the category more variety and could help brands reach consumers looking for different experiences.
Nicotine Strength Is Only Part of the Review
The FDA does not base its decisions solely on the number printed on a nicotine pouch package.
The agency evaluates the product's design, formulation, materials, and other characteristics that can influence nicotine exposure and the speed at which nicotine is delivered.
The amount of nicotine listed on the label therefore does not tell the entire story about how a product behaves.
The FDA also considers the presence of harmful and potentially harmful constituents. In its recent evaluations, the agency found that the newly authorized nicotine pouches contained lower levels of most harmful and potentially harmful constituents than other oral and smokeless tobacco products.
Some constituents were present at levels that were too low to quantify.
That information helps explain why the FDA's regulatory decisions involve considerably more than simply checking nicotine strength and flavor names.
Potential Benefits Depend on Who Uses Them
Another important part of the FDA's analysis involves the potential impact on people who already use tobacco.
For people who smoke cigarettes or use smokeless tobacco, completely switching to an FDA-authorized nicotine pouch can reduce exposure to many harmful chemicals associated with traditional tobacco products.
However, the distinction between switching and supplementing is important.
Someone who continues smoking while also using nicotine pouches has not made the same complete switch considered in the FDA's potential risk-reduction analysis.
The agency therefore does not present nicotine pouches as risk-free alternatives. Instead, its evaluation considers potential benefits and risks at the population level, including the possibility that some current tobacco users may move away from more harmful products.
The Regulatory Process Is Also Changing
The recent decisions provide another example of the FDA's nicotine pouch pilot program.
The program was created to help make the premarket tobacco product application process more efficient. According to the FDA, the pilot has helped the agency resolve issues faster, reduce response times related to deficiency letters, and improve the efficiency of scientific reviews.
The agency has indicated that lessons from the pilot could also be applied to other premarket tobacco product applications.
That could become increasingly important as manufacturers continue submitting new nicotine pouch products for consideration.
43 Nicotine Pouches Are Now Authorized
Following the August 21 ZYN ULTRA decision, the FDA said 43 nicotine pouch products had received marketing authorization in the United States.
That number reflects the rapid development of a category that has become increasingly visible in convenience stores, tobacco retailers, and other markets.
The FDA has also emphasized that only authorized nicotine pouch products may lawfully be marketed in the United States. Products that have not received the required authorization can be subject to enforcement.
As the authorized market grows, that regulatory distinction is becoming more significant for both manufacturers and retailers.
What Comes Next for Nicotine Pouches?
The latest authorizations suggest that the U.S. nicotine pouch market is entering a more competitive phase.
Brands are no longer competing solely on whether they offer nicotine. Flavor variety, nicotine strength, formulation, product design, and regulatory status are becoming increasingly important parts of the category.
ZYN ULTRA's new 9 mg and 11 mg offerings expand the upper end of its newly authorized lineup, while on!'s new products add lower-strength choices and more unusual flavor profiles.
At the same time, the FDA continues to stress that marketing authorization does not equal safety. Nicotine remains addictive, and the agency's review is designed to weigh potential benefits against risks rather than declare a product harmless.
For the nicotine pouch industry, the recent decisions represent another major step toward a larger and more regulated U.S. market.
